查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2135478

益生菌市場：全球市場預測，2026-2032年

Psychobiotics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，益生菌市場將成長至 22.6 億美元，複合年成長率為 8.23%。

主要市場統計數據
基準年 2025 13億美元
預計年份：2026年 14.3億美元
預測年份 2032 22.6億美元
複合年成長率 (%) 8.23%

益生菌療法：微生物組與大腦連結的新領域

益生菌療法是指研究益生菌、益生元及其他相關微生物組介入措施對情緒、壓力、認知功能、睡眠及其他心理健康方面影響的療法。該領域基於腸道和大腦透過神經、免疫、內分泌和代謝途徑相互作用的證據。目前研究仍在進行中，臨床結果因菌株、配方、目標族群和終點指標而異。因此，應將益生菌療法視為一個不斷發展的科學和治療領域，而不是單一的產品類型。

轉化科學正推動益生菌療法走向「精準」和「實證」。

研究趨勢正從對腸道健康的廣泛論斷轉向更具體的假設，將微生物功能與明確的心理和神經系統結果聯繫起來。研究更重視菌株層級的特徵分析、代謝物生成、宿主反應、飲食環境以及臨床檢驗的指標。這種轉變也提升了可重複研究設計、明確目標族群、合適的對照組以及符合監管要求的代表性的重要性。因此，產品開發正變得更加循證，並與診斷、營養和臨床護理更加緊密地結合。

人工智慧正在加速發現，但同時，它也提高了檢驗。

人工智慧 (AI) 可協助研究人員整合微生物組定序、代謝體學、飲食記錄、臨床數據和患者報告結果 (PRO)，從而識別傳統分析方法難以發現的模式。其潛在應用包括生物標記發現、候選菌株篩選、配方最佳化、患者分層和治療反應監測。然而，演算法相關性並不能建立因果關係。要將 AI 洞察作為健康聲明和醫療決策的依據，穩健的外部檢驗、透明的資料管治、敏感健康資訊的保護以及前瞻性臨床試驗仍然至關重要。

區域差異反映了研究能力、法規和消費者接受度。

在北美，先進的微生物組研究、活躍的臨床研究以及對個人化營養的濃厚興趣匯聚一堂，而監管要求則促使人們必須仔細區分膳食補充劑、食品和醫療產品。在歐洲，科學證據、安全性和經授權的健康資訊傳播尤其重要，歐盟（EU）在各國實施的同時，也提供了至關重要的協調政策架構。亞太地區在活躍的研究活動和多樣化的飲食及微生物特徵方面具有優勢。澳洲、中國、印度、日本和韓國分別從各自獨特的臨床、學術和消費者健康視角做出貢獻。在拉丁美洲，人們對營養、消化健康和當地研究重點的興趣日益濃厚，其中巴西和墨西哥是重要的參考市場。在中東和非洲，儘管預防醫學和營養領域存在機遇，但監管和醫療保健環境各不相同，在研究基礎設施、取得途徑和產品監管方面仍然存在差異。

經濟和政策集團塑造了合作和市場進入。

東南亞國協為研究飲食、種族和微生物組多樣性提供了多樣化的環境，而金磚國家則擁有重要的研究、製造和醫療保健環境，但監管體系各不相同。歐盟支持跨境科學和政策協調，但各國醫療保健和報銷條件仍是重要因素。七國集團（G7）國家通常擁有強大的生物醫學研究能力、完善的監管機構以及對臨床證據的高要求。海灣合作理事會（GCC）國家日益重視醫療保健、預防醫學和研究能力的現代化，但產品註冊和臨床應用可能因司法管轄區而異。北約成員國擁有多樣化的醫療保健系統和研究生態系統，合作研究可以受益於通用的科學標準，但商業性開發仍依賴各國的法規。

每個國家的優先事項包括轉化研究和為遵守監管規定做準備。

美國和加拿大擁有強大的科學研究和臨床生態系統，注重證據品質、個人化營養和監管分類。英國、法國、德國、義大利和西班牙在各自獨特的醫療保健和政策環境下，具備成熟的微生物組、營養和神經精神病學研究能力。中國、日本和韓國擁有先進的生命科學基礎設施，並對機能性食品和預防醫學有著濃厚的興趣；印度則以其豐富的科研人才、多樣化的飲食習慣和蓬勃發展的生物技術活動而著稱。澳洲在完善的法律規範內支持臨床營養和微生物組研究。在巴西和墨西哥，不同族群對微生物組科學和功能性營養的興趣日益濃厚。俄羅斯擁有相關的科學研究能力，但其研究合作、供應鏈和監管聯絡可能會受到地緣政治環境的影響。

產業領導者應共同建構證據、信任和互通性。

領導者在選擇菌株、配方或目標族群之前，應先明確定義準確且具臨床意義的結局指標。研發計畫應充分利用嚴謹的隨機對照試驗、標準化的微生物組和代謝體學方法、檢驗的心理健康檢測法以及透明的不利事件報告機制。臨床醫生、微生物學家、營養科學家、數據專家和監管機構之間的夥伴關係能夠提升轉化研究的品質。各機構應避免做出過多的因果關係聲明，建立從菌株鑑定到生產的全程品管，並設計注重隱私權保護的資料系統。區域策略應充分考慮飲食習慣、當地法規、醫療保健路徑以及符合文化背景的溝通方式，而非假定單一配方或證據包具有普遍適用性。

調查方法：對科學、監管和地方背景的證據進行三角驗證。

本執行摘要是基於對益生菌領域的系統評估，評估依據包括已確立的微生物組和腦軸科學概念、臨床開發原則、監管考慮、人工智慧應用以及特定的區域、人群和國家框架。摘要中的觀點從檢驗的證據類別中進行定性整合，這些證據類別包括同行評審的研究、臨床試驗實踐、公共監管指南以及公認的醫療保健和營養政策背景。由於所提供的參考文獻未明確市場類別或提供基礎資料集，因此本摘要有意省略了市場估算、預測、市場佔有率和未經證實的定量聲明。

心理益生菌療法將憑藉具體論點和更有力的臨床證據取得進展。

益生菌有望將微生物組科學與心理健康和神經系統疾病治療聯繫起來，但其發展取決於能否解決作用機制、一致性、永續性、安全性以及患者選擇等方面的關鍵挑戰。最可靠的前進方向是結合菌株層面的科學研究、臨床相關的終點指標、負責任的人工智慧、穩健的生產流程以及相應的管理體制。重視可重複性和透明溝通的機構將更有能力把有前景的微生物組和大腦研究成果轉化為可靠有效的干預措施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 益生菌市場：依菌株類型分類

  • 芽孢桿菌
  • 雙叉桿菌
    • 雙歧桿菌
    • B. longum
  • 乳酸桿菌
    • 植物乳桿菌
    • 鼠李糖乳桿菌

第8章 精神益生菌市場：依產品形式分類

  • 膠囊
  • 液體
  • 粉末
  • 藥片

第9章 精神益生菌市場：依應用領域分類

  • 機能性食品和飲料
    • 乳製品
    • 非乳製品
  • 營養保健品和膳食補充劑
    • 多微生物菌株
    • 單菌株
  • 製藥

第10章 益生菌市場：依最終用戶分類

  • 成人
  • 老年人
  • 兒童

第11章 精神益生菌市場：依通路分類

  • 離線
    • 藥局
    • 零售店
    • 專賣店
  • 線上
    • 直接面對消費者
    • 電子商務

第12章 精神益生菌市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 益生菌市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 精神益生菌市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Archer Daniels Midland Company
  • Bifodan AS
  • BioGaia AB
  • Chr Hansen Holding AS
  • Danone SA
  • Deerland Probiotics & Enzymes
  • DuPont Nutrition & Health
  • Gnosis by Lesaffre
  • Groupe Danone
  • Kerry Group plc
  • Lallemand Health Solutions
  • Lesaffre Group
  • Morinaga Milk Industry Co Ltd
  • Nature's Bounty Co
  • Nestle Health Science
  • Novozymes AS
  • Probi AB
  • Sabinsa Corporation
  • UAS Laboratories
  • Winclove Probiotics BV
  • Yakult Honsha Co Ltd

第17章 主要專家

Product Code: MRR-961F26FD6469

The Psychobiotics Market is projected to grow by USD 2.26 billion at a CAGR of 8.23% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.30 billion
Estimated Year [2026] USD 1.43 billion
Forecast Year [2032] USD 2.26 billion
CAGR (%) 8.23%

Psychobiotics: An Emerging Frontier in the Microbiome-Brain Connection

Psychobiotics refers to probiotic, prebiotic, and related microbiome-based interventions investigated for effects on mood, stress, cognition, sleep, and other aspects of mental health. The field draws on evidence that the gut and brain communicate through neural, immune, endocrine, and metabolic pathways. Research remains active, with clinical findings varying by strain, formulation, population, and endpoint; therefore, psychobiotics should be evaluated as a developing scientific and therapeutic category rather than a uniform product class.

Translative Science Is Shifting Psychobiotics Toward Precision and Evidence

The landscape is moving from broad claims about gut health toward more specific hypotheses linking microbial functions with defined psychological or neurological outcomes. Greater attention is being given to strain-level characterization, metabolite production, host response, dietary context, and clinically validated measures. This shift is also increasing the importance of reproducible trial design, clearly defined populations, appropriate comparators, and regulatory-compliant language. Product development is consequently becoming more evidence-led and more closely connected to diagnostics, nutrition, and clinical care.

Artificial Intelligence Is Accelerating Discovery While Raising Validation Requirements

Artificial intelligence can help researchers integrate microbiome sequencing, metabolomics, dietary records, clinical data, and patient-reported outcomes to identify patterns that are difficult to detect with conventional analysis. Its potential applications include biomarker discovery, candidate-strain selection, formulation optimization, patient stratification, and monitoring of treatment response. However, algorithmic associations do not establish causality. Robust external validation, transparent data governance, protection of sensitive health information, and prospective clinical testing remain essential before AI-derived insights are used to support health claims or care decisions.

Regional Differences Reflect Research Capacity, Regulation, and Consumer Adoption

North America combines advanced microbiome research, active clinical investigation, and strong interest in personalized nutrition, while regulatory expectations require careful distinction between supplements, foods, and medical products. Europe places notable emphasis on scientific substantiation, safety, and permitted health communications, with the European Union providing an important harmonized policy context alongside national implementation. Asia-Pacific benefits from substantial research activity and diverse dietary and microbial profiles; Australia, China, India, Japan, and South Korea each contribute distinct clinical, academic, and consumer-health perspectives. Latin America shows growing interest shaped by nutrition, digestive health, and local research priorities, with Brazil and Mexico as important reference markets. The Middle East and Africa present varied regulatory and healthcare environments, with opportunities linked to preventive health and nutrition but continuing differences in research infrastructure, access, and product oversight.

Economic and Policy Groupings Shape Collaboration and Market Access

ASEAN countries offer a diverse setting for studying diet, ethnicity, and microbiome variation, while BRICS members span major research, manufacturing, and population-health environments with differing regulatory systems. The European Union supports cross-border scientific and policy coordination, although national healthcare and reimbursement conditions remain relevant. G7 economies generally provide strong biomedical research capabilities, sophisticated regulatory institutions, and high expectations for clinical evidence. GCC states are increasingly focused on healthcare modernization, preventive health, and research capacity, but product registration and clinical adoption can vary by jurisdiction. NATO members encompass diverse health systems and research ecosystems; collaboration may benefit from shared scientific standards, while commercial deployment still depends on each country's rules.

Country Priorities Range from Translational Research to Regulatory Readiness

The United States and Canada have influential research and clinical ecosystems, with attention to evidence quality, personalized nutrition, and regulatory classification. The United Kingdom, France, Germany, Italy, and Spain contribute established microbiome, nutrition, and neuropsychiatric research capabilities within distinct national healthcare and policy settings. China, Japan, and South Korea combine advanced life-science infrastructure with strong interest in functional foods and preventive health, while India brings substantial scientific talent, dietary diversity, and growing biotechnology activity. Australia supports clinical nutrition and microbiome research within a well-developed regulatory framework. Brazil and Mexico reflect expanding interest in microbiome science and functional nutrition across diverse populations. Russia maintains relevant scientific capabilities, although research collaboration, supply chains, and regulatory engagement may be affected by geopolitical conditions.

Industry Leaders Should Build Evidence, Trust, and Interoperability Together

Leaders should define precise, clinically meaningful outcomes before selecting strains, formulations, or target populations. Development programs should use rigorous randomized studies, standardized microbiome and metabolomic methods, validated mental-health measures, and transparent reporting of adverse events. Partnerships across clinicians, microbiologists, nutrition scientists, data specialists, and regulators can improve translational quality. Organizations should avoid overstated causal claims, establish quality controls from strain identity through manufacturing, and design privacy-conscious data systems. Regional strategies should account for dietary patterns, local regulations, healthcare pathways, and culturally appropriate communication rather than assuming that one formulation or evidence package will transfer universally.

Methodology: Evidence Triangulation Across Science, Regulation, and Regional Context

This executive summary is based on a structured assessment of the psychobiotics field through established scientific concepts concerning the microbiome-brain axis, clinical-development principles, regulatory considerations, artificial-intelligence applications, and the specified regional, group, and country frameworks. Insights are synthesized qualitatively from verifiable categories of evidence, including peer-reviewed research, clinical-trial practice, public regulatory guidance, and recognized healthcare and nutrition policy contexts. Because the supplied reference identifies the market category but provides no underlying dataset, the summary intentionally excludes market estimates, shares, forecasts, and unsupported quantitative claims.

Psychobiotics Will Advance Through Specific Claims and Stronger Clinical Proof

Psychobiotics has the potential to connect microbiome science with mental-health and neurological care, but progress depends on resolving substantial questions about mechanisms, consistency, durability, safety, and appropriate patient selection. The most credible path forward combines strain-level science, clinically relevant endpoints, responsible AI, robust manufacturing, and jurisdiction-specific regulatory discipline. Organizations that prioritize reproducibility and transparent communication will be better positioned to translate promising microbiome-brain findings into trusted, useful interventions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Psychobiotics Market, by Strain Type

  • 7.1. Introduction
  • 7.2. Bacillus
  • 7.3. Bifidobacterium
    • 7.3.1. B Bifidum
    • 7.3.2. B Longum
  • 7.4. Lactobacillus
    • 7.4.1. L Plantarum
    • 7.4.2. L Rhamnosus

8. Psychobiotics Market, by Product Form

  • 8.1. Introduction
  • 8.2. Capsule
  • 8.3. Liquid
  • 8.4. Powder
  • 8.5. Tablet

9. Psychobiotics Market, by Application

  • 9.1. Introduction
  • 9.2. Functional Food & Beverage
    • 9.2.1. Dairy-Based
    • 9.2.2. Non-Dairy
  • 9.3. Nutraceutical & Dietary Supplement
    • 9.3.1. Multi-Strain
    • 9.3.2. Single-Strain
  • 9.4. Pharmaceutical

10. Psychobiotics Market, by End User

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Psychobiotics Market, by Distribution

  • 11.1. Introduction
  • 11.2. Offline
    • 11.2.1. Pharmacy
    • 11.2.2. Retail Store
    • 11.2.3. Specialty Store
  • 11.3. Online
    • 11.3.1. Direct-To-Consumer
    • 11.3.2. E-Commerce

12. Psychobiotics Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Psychobiotics Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Psychobiotics Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Archer Daniels Midland Company
  • 16.2. Bifodan A S
  • 16.3. BioGaia AB
  • 16.4. Chr Hansen Holding A S
  • 16.5. Danone S A
  • 16.6. Deerland Probiotics & Enzymes
  • 16.7. DuPont Nutrition & Health
  • 16.8. Gnosis by Lesaffre
  • 16.9. Groupe Danone
  • 16.10. Kerry Group plc
  • 16.11. Lallemand Health Solutions
  • 16.12. Lesaffre Group
  • 16.13. Morinaga Milk Industry Co Ltd
  • 16.14. Nature's Bounty Co
  • 16.15. Nestle Health Science
  • 16.16. Novozymes A S
  • 16.17. Probi AB
  • 16.18. Sabinsa Corporation
  • 16.19. UAS Laboratories
  • 16.20. Winclove Probiotics B V
  • 16.21. Yakult Honsha Co Ltd

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Psychobiotics Market, Years Considered for the Study
  • FIGURE 2. Global Psychobiotics Market, Research Design
  • FIGURE 3. Global Psychobiotics Market, Research Framework
  • FIGURE 4. Global Psychobiotics Market, Data Triangulation
  • FIGURE 5. Global Psychobiotics Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Psychobiotics Market Size, by Strain Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Psychobiotics Market Size, by Strain Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Psychobiotics Market Size, by Product Form, 2025 vs 2032 (%)
  • FIGURE 9. Global Psychobiotics Market Size, by Product Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Psychobiotics Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 11. Global Psychobiotics Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Psychobiotics Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global Psychobiotics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Psychobiotics Market Size, by Distribution, 2025 vs 2032 (%)
  • FIGURE 15. Global Psychobiotics Market Size, by Distribution, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Psychobiotics Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Psychobiotics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Psychobiotics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Psychobiotics Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Psychobiotics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Psychobiotics Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Psychobiotics Market Segmentation & Coverage
  • TABLE 2. Global Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 4. Global Bacillus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Bacillus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Bacillus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Bifidobacterium Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Bifidobacterium Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Bifidobacterium Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global B Bifidum Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global B Bifidum Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global B Bifidum Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global B Longum Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global B Longum Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global B Longum Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Lactobacillus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Lactobacillus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Lactobacillus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global L Plantarum Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global L Plantarum Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global L Plantarum Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global L Rhamnosus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global L Rhamnosus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global L Rhamnosus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 26. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Powder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Powder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Powder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 39. Global Functional Food & Beverage Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Functional Food & Beverage Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Functional Food & Beverage Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Dairy-Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Dairy-Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Dairy-Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Non-Dairy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Non-Dairy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Non-Dairy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Nutraceutical & Dietary Supplement Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Nutraceutical & Dietary Supplement Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Nutraceutical & Dietary Supplement Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Multi-Strain Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Multi-Strain Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Multi-Strain Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Single-Strain Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Single-Strain Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Single-Strain Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Pharmaceutical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Pharmaceutical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Pharmaceutical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 61. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 71. Global Offline Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Offline Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Offline Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global Retail Store Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Retail Store Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Retail Store Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Specialty Store Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Specialty Store Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Specialty Store Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Online Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Online Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Online Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Direct-To-Consumer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Direct-To-Consumer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Direct-To-Consumer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global E-Commerce Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Global E-Commerce Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. Global E-Commerce Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 92. Global Psychobiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific Psychobiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 95. Asia-Pacific Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 96. Asia-Pacific Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 97. Asia-Pacific Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 98. Asia-Pacific Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 99. Asia-Pacific Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 100. Asia-Pacific Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 101. Asia-Pacific Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 102. Asia-Pacific Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 103. Asia-Pacific Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 104. Asia-Pacific Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 105. North America Psychobiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. North America Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 107. North America Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 108. North America Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 109. North America Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 110. North America Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 111. North America Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 112. North America Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 113. North America Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 114. North America Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 115. North America Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 116. North America Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 117. Latin America Psychobiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 118. Latin America Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 119. Latin America Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 120. Latin America Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 121. Latin America Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 122. Latin America Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 123. Latin America Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 124. Latin America Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 125. Latin America Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 126. Latin America Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 127. Latin America Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 128. Latin America Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 129. Europe Psychobiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 130. Europe Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 131. Europe Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 132. Europe Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 133. Europe Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 134. Europe Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 135. Europe Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 136. Europe Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 137. Europe Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 138. Europe Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 139. Europe Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 140. Europe Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 141. Middle East Psychobiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 142. Middle East Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 143. Middle East Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 144. Middle East Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 145. Middle East Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 146. Middle East Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 147. Middle East Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 148. Middle East Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 149. Middle East Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 150. Middle East Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 151. Middle East Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 152. Middle East Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 153. Africa Psychobiotics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 154. Africa Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 155. Africa Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 156. Africa Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 157. Africa Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 158. Africa Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 159. Africa Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 160. Africa Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 161. Africa Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 162. Africa Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 163. Africa Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 164. Africa Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 165. Global Psychobiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 166. ASEAN Psychobiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 167. ASEAN Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 168. ASEAN Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 169. ASEAN Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 170. ASEAN Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 171. ASEAN Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 172. ASEAN Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 173. ASEAN Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 174. ASEAN Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 175. ASEAN Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 176. ASEAN Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 177. ASEAN Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 178. GCC Psychobiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 179. GCC Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 180. GCC Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 181. GCC Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 182. GCC Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 183. GCC Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 184. GCC Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 185. GCC Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 186. GCC Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 187. GCC Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 188. GCC Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 189. GCC Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 190. European Union Psychobiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 191. European Union Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 192. European Union Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 193. European Union Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 194. European Union Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 195. European Union Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 196. European Union Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 197. European Union Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 198. European Union Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 199. European Union Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 200. European Union Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 201. European Union Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 202. BRICS Psychobiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 203. BRICS Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 204. BRICS Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 205. BRICS Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 206. BRICS Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 207. BRICS Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 208. BRICS Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 209. BRICS Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 210. BRICS Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 211. BRICS Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 212. BRICS Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 213. BRICS Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 214. G7 Psychobiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 215. G7 Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 216. G7 Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 217. G7 Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 218. G7 Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 219. G7 Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 220. G7 Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 221. G7 Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 222. G7 Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 223. G7 Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 224. G7 Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 225. G7 Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 226. NATO Psychobiotics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 227. NATO Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 228. NATO Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 229. NATO Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 230. NATO Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 231. NATO Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 232. NATO Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 233. NATO Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 234. NATO Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 235. NATO Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 236. NATO Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 237. NATO Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 238. Global Psychobiotics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 239. United States Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 240. United States Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 241. United States Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 242. United States Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 243. United States Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 244. United States Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 245. United States Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 246. United States Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 247. United States Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 248. United States Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 249. United States Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 250. United States Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 251. Canada Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 252. Canada Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 253. Canada Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 254. Canada Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 255. Canada Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 256. Canada Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 257. Canada Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 258. Canada Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 259. Canada Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 260. Canada Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 261. Canada Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 262. Canada Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 263. Mexico Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 264. Mexico Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 265. Mexico Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 266. Mexico Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 267. Mexico Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 268. Mexico Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 269. Mexico Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 270. Mexico Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 271. Mexico Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 272. Mexico Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 273. Mexico Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 274. Mexico Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 275. Brazil Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 276. Brazil Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 277. Brazil Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 278. Brazil Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 279. Brazil Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 280. Brazil Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 281. Brazil Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 282. Brazil Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 283. Brazil Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 284. Brazil Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 285. Brazil Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 286. Brazil Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 287. United Kingdom Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 288. United Kingdom Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 289. United Kingdom Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 290. United Kingdom Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 291. United Kingdom Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 292. United Kingdom Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 293. United Kingdom Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 294. United Kingdom Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 295. United Kingdom Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 296. United Kingdom Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 297. United Kingdom Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 298. United Kingdom Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 299. Germany Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 300. Germany Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 301. Germany Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 302. Germany Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 303. Germany Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 304. Germany Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 305. Germany Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 306. Germany Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 307. Germany Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 308. Germany Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 309. Germany Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 310. Germany Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 311. France Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 312. France Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 313. France Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 314. France Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 315. France Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 316. France Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 317. France Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 318. France Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 319. France Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 320. France Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 321. France Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 322. France Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 323. Russia Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 324. Russia Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 325. Russia Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 326. Russia Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 327. Russia Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 328. Russia Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 329. Russia Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 330. Russia Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 331. Russia Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 332. Russia Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 333. Russia Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 334. Russia Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 335. Italy Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 336. Italy Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 337. Italy Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 338. Italy Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 339. Italy Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 340. Italy Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 341. Italy Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 342. Italy Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 343. Italy Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 344. Italy Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 345. Italy Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 346. Italy Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 347. Spain Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 348. Spain Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 349. Spain Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 350. Spain Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 351. Spain Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 352. Spain Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 353. Spain Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 354. Spain Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 355. Spain Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 356. Spain Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 357. Spain Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 358. Spain Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 359. China Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 360. China Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 361. China Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 362. China Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 363. China Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 364. China Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 365. China Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 366. China Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 367. China Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 368. China Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 369. China Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 370. China Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 371. India Psychobiotics Market Size, 2017-2032 (USD Million)
  • TABLE 372. India Psychobiotics Market Size, by Strain Type, 2017-2032 (USD Million)
  • TABLE 373. India Psychobiotics Market Size, by Bifidobacterium, 2017-2032 (USD Million)
  • TABLE 374. India Psychobiotics Market Size, by Lactobacillus, 2017-2032 (USD Million)
  • TABLE 375. India Psychobiotics Market Size, by Product Form, 2017-2032 (USD Million)
  • TABLE 376. India Psychobiotics Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 377. India Psychobiotics Market Size, by Functional Food & Beverage, 2017-2032 (USD Million)
  • TABLE 378. India Psychobiotics Market Size, by Nutraceutical & Dietary Supplement, 2017-2032 (USD Million)
  • TABLE 379. India Psychobiotics Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 380. India Psychobiotics Market Size, by Distribution, 2017-2032 (USD Million)
  • TABLE 381. India Psychobiotics Market Size, by Offline, 2017-2032 (USD Million)
  • TABLE 382. India Psychobiotics Market Size, by Online, 2017-2032 (USD Million)
  • TABLE 383. Japan Psychobiotics Market Size, 2017-